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drug use based on therapeutic category, genitourinary products
were found to have the highest potential for inappropriate
prescribing.
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OBJECTIVE: Recent studies have demonstrated increased short-
term mortality among older adults with dementia who are pre-
scribed antipsychotic drug therapy. Despite these ﬁndings, use of
antipsychotics remains common in long-term care (LTC) homes.
This study explores the real-world implications of variations in
antipsychotic dispensing across LTC homes by assessing whether
homes with higher rates of dispensing had higher rates of mor-
tality among their residents. METHODS: Retrospective cohort
study of 47,308 older adults with no history of psychoses who
were newly admitted to 503 Ontario LTC homes between April
1, 2000, and March 31, 2004. Facilities were classiﬁed into
quintiles according to their mean antipsychotic dispensing rates.
All-cause mortality was examined across quintiles at 30 and 120
days after admission. RESULTS: The rate of antipsychotic dis-
pensing ranged from 0 to 44.8% across LTC homes. The abso-
lute baseline difference in 30-day (120-day) mortality between
facilities dispensing highest versus lowest rates of antipsychotics
was 1.4% (4.1%). Mortality was greater in the highest rate
homes (adjusted hazard ratio 1.29, conﬁdence interval 1.11 to
1.51 at 30 days; adjusted hazard ratio 1.28, conﬁdence interval
1.17 to 1.39 at 120 days) compared to the lowest rate homes.
CONCLUSION: Residents newly admitted to LTC homes with
higher antipsychotic dispensing rates had increased risk of short-
term mortality.
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OBJECTIVE: The primary objective of this analysis was to
determine whether generic switching of warfarin was related to
increased hospitalization and emergency room use among elderly
chronic warfarin users. METHODS: The “switchability” of
narrow therapeutic index (NTI) drugs has been debated in the
literature. The issue is not whether generic products can safely be
substituted for brand products, but whether problems can result
from switches among manufacturers during repeated reﬁlls.
Medicare Part D and A records for 2006 were pulled for all
non-ESRD, chronic warfarin users in California, Florida, and
Mississippi age 65+. Chronic warfarin users were deﬁned as
patients with 3+ warfarin prescriptions covering 180+ days of
therapy. Recipients’ records were evaluated for hospital admis-
sions or ER visits during the treatment period. The hospital
services also were evaluated to determine if they resulted from
bleeding episodes or potential prophylactic use of warfarin based
on diagnosis codes. RESULTS: Data were available for 160,929
chronic warfarin users. After controlling for age, race, and
gender, the odds ratio for patients with generic switches com-
pared to those without was 1.61 for general hospital admissions
and 1.47 for general ER visits. Similar ratios were found for
hospital admissions related to bleeding episodes (1.51)/potential
prophylactic use (1.53) and ER visits related to bleeding episodes
(1.34)/potential prophylactic use (1.44). The average monthly
cost for hospital and ER services was 38% higher for the patients
with generic switches ($2121 vs. $1553). CONCLUSION: The
results suggest that generic switching of NTI drugs, such as
warfarin, can signiﬁcantly increase the likelihood of hospitaliza-
tion and ER visits and result in increased costs of care. To provide
better therapy management for patients on NTI drugs, pharma-
cists should avoid generic switching between manufacturers
and/or notify the appropriate providers when generic switches do
occur.
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OBJECTIVE: The objective was to evaluate the relationship
between low dose warfarin therapy and hospital utilization.
This information will help to evaluate this as a quality of care
indicator in elderly patients. METHODS: An issue in chronic
warfarin therapy is the availability of time and resources nec-
essary to adequately manage patients on anticoagulation
therapy. Providers may err on the side of under-dosing due to
fears of bleeding episodes. Medicare Part D and A records for
2006 were pulled for all non-ESRD, chronic warfarin users in
California, Florida, and Mississippi age 65+. Chronic warfarin
users were deﬁned as patients with 3+ warfarin prescriptions
covering 180+ days of therapy. Average dose was computed by
dividing the total mgs of warfarin dispensed from the ﬁrst pre-
scription to the next to last prescription and dividing by the
number of days between the ﬁrst and last prescription ﬁlls. Low
average dose was deﬁned as <=.5 mgs/day. Each recipient’s
records were evaluated for hospital admissions or ER visits
during the treatment period. RESULTS: Data were available for
160,929 chronic warfarin users. After controlling for age, race,
and gender, the odds ratios for patients on low average doses
compared to higher average doses were 1.42 for general hos-
pital admissions and 1.21 for general ER visits. The average
monthly cost for hospital and ER services was 85% higher for
the patients with low average doses ($2524 vs. $1364). CON-
CLUSION: The results indicate patients on average warfarin
doses of 2.5 mgs/day or less have greater odds of hospital
admissions or ER visits; and cost CMS more for these services.
This suggests that low average dose warfarin therapy is a
potential indicator that these patients are in need of better care;
and that CMS should consider payment for anticoagulation
management services that will maintain therapeutic INR levels
while minimizing bleeding risks.
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OBJECTIVE: Little is known about the quality of drug admin-
istration and safety in German nursing homes. In 2002 a group
of health authority pharmacists in the federal state of North
Rhine-Westphalia inspected the quality of drug supply in 120
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nursing homes. As this study was not representative, it cannot be
used to draw reliable conclusions. Therefore, the aim of the
current study was to quantify the number of drug administration
errors in German nursing homes. The focus was on checking the
administration of regularly scheduled solid oral medication.
METHODS: The prospective study was carried out in three
nursing homes during a period of eight weeks. The drug admin-
istration errors were divided into seven categories: wrong time
of administration, wrong dosage, wrong drug, missing drug,
surplus drug, incorrect pill division and damaged drug.
RESULTS: The study included 196 residents. In total, 8798 daily
doses were screened. This equals a total number of 48,512
inspected single medications. On average, every nursing home
resident received 5.4 solid oral drugs per day. In 53% of the
nursing home residents one or more drug administration errors
were detected. Based on the 8798 screened daily doses the error
rate was 7.3%. The majority of all drug supply errors (50%)
occurred in the category incorrect pill division. This is followed
by the category missing drug with 22%, surplus drug with 10%,
wrong time of administration with 8%, damaged drug with 6%,
wrong dosage with 4% and wrong drug with 0%. CONCLU-
SION: The ﬁndings of the study show that there is still a need for
action with regard to drug administration in German nursing
homes.
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OBJECTIVE: The opponents of the socialization of health care
hypothesize that socialization of health care could lead to
decrease quality of care. The aim of our study was to compare
the quality of care delivered to a privately insured population
compared to those covered by government subsidized Medicaid
plan in the same region. METHODS: Administrative claims
data from July 2004 through June 2005 were used from a
private health plan and the Medicaid plan within the same state
in the Southeastern US. Two quality indicators from the Health
Plan Employer Data and Information Set (HEDIS) were adapted
and used to compare compliance rates between the privately
insured and Medicaid populations (Table 1). Based on the speci-
ﬁcations of each indicator, children who met relevant criteria
were identiﬁed as the denominator. Of those, children that
received the indicated intervention were identiﬁed as the
numerator. Population-level rates were calculated for each
quality indicator for both plans. RESULTS: Children in the
private health plan received the indicated quality care much
more frequently than the Medicaid population, with nearly
3-fold differences in compliance rates. Varicella zoster virus
(VZV) vaccines and measles, mumps and rubella (MMR) vac-
cines were included in the analysis for 2 year old children. The
private plan had a denominator of 4222 children and the Med-
icaid plan had 15,653 children for both measures. Eighty-two
percent of private plan children received a VZV vaccine com-
pared to 29% of Medicaid children. Eighty-four percent of
private plan children received an MMR vaccine compared to
29% of Medicaid children. CONCLUSION: Children covered
by Medicaid plans are signiﬁcantly less likely to receive quality
health care than compared to those who have private insurance
coverage. Further studies are needed to investigate to what
degree this wide disparity is driven by socioeconomic factors
and the socialization of health care.
MUSCULAR-SKELETAL DISORDERS—
Clinical Outcomes Studies
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OBJECTIVE: While bisphosphonates have been available for
many years, new drugs in this class have recently become avail-
able. We sought to understand whether differences exist on
fracture risk and adverse events among oral (i.e., alendronate,
risedronate, ibandronate) and intravenous (i.e., ibandronate,
pamidronate, and zoledronic acid) bisphosphonates available in
the United States in postmenopausal women. METHODS: A
search of the English-language literature in Medline and
Cochrane databases was conducted from 1997 to 2007 using
combinations of these search terms: bisphosphonates, alendr-
onate, risedronate, zoledronic acid, pamidronate, ibandronate,
fracture, adverse events, and osteoporosis. Articles were included
if they were meta-analyses or randomized controlled trials (RCT)
and provided information on fracture risk and adverse events.
RESULTS: In the most recent meta-analysis, alendronate
(n = 12,099 patients; 11 trials) and risedronate (n = 13,795
patients; 6 trials) reduced the risk of vertebral fractures
(RR:0.55, 95%CI 0.45–0.67; RR:0.61, 95%CI 0.50–0.76) and
non-vertebral fractures (RR:0.84, 95%CI 0.74–0.94; RR:0.80,
95%CI 0.72–0.90), including hip fractures (RR:0.61, 95%CI
0.40–0.92; RR:0.74, 95%CI 0.59–0.94). Similarly, in a RCT
among 7765 women, the incidence of vertebral fractures, non-
vertebral, and hip fractures was signiﬁcantly reduced with
zoledronic acid (RR:0.30, 95%CI 0.24–0.38; RR:0.75, 95%CI
0.64–0.87; RR:0.59, 95%CI 0.42–0.83). In contrast, oral iban-
dronate (n = 1952) lowered the risk of vertebral fractures
(RR:0.62, 95%CI 0.41–0.75) but not nonvertebral fractures.
Data on fracture risk with pamidronate were not identiﬁed.
Adverse events were similar between bisphosphonates and
placebo in all included studies, except with zoledronic acid where
serious atrial ﬁbrillation (1.3% vs. 0.5%; p < 0.001), an increase
in Scr >0.5 mg/dL (1.2% vs. 0.4%; p = 0.001), and urinary
protein >2+ (0.5% vs. 0.2%; p = 0.06) were higher with treat-
ment compared to placebo. CONCLUSION: This evidenced-
based literature review shows that clinical differences among
bisphosphonates exist. This suggests that selection of bisphos-
phonates needs to be individualized to maximize the desired
effect and minimize risks.
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OBJECTIVE: Three biological agents (adalimumab, etanercept
and inﬂiximab) are registered for psoriatic arthritis (PsA) by the
EMEA or the FDA. Our objectives were to compare the efﬁcacy
of the available biologicals in PsA and to compare their effect
sizes by standardized improvement criteria of signs and symp-
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